BriaCell Therapeutics
(TSX) BCT
BriaCell Therapeutics Financials at a Glance
Market Cap
CA$48.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$0.00
Net Income (TTM)
-$30.65M
EPS (TTM)
-CA$16.87
P/E Ratio
-0.33
Dividend
CA$0.00
Beta (Volatility)
1.09 (Average)
Dividend
CA$0.00
Beta (Volatility)
1.09 (Average)
Price
CA$5.58
Volume
14,492
Open
CA$5.30
Price
CA$5.58
Volume
14,492
Open
CA$5.30
Previous Close
CA$5.58
Daily Range
CA$5.30 - CA$5.64
52-Week Range
CA$3.68 - CA$28.30
Estimated Earnings Date
Mar 10, 2026
Dividend
CA$0.00
Beta (Volatility)
1.09 (Average)
Price
CA$5.58
Volume
14,492
Open
CA$5.30
Previous Close
CA$5.58
Daily Range
CA$5.30 - CA$5.64
52-Week Range
CA$3.68 - CA$28.30
Estimated Earnings Date
Mar 10, 2026
BCT News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout BriaCell Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
17
CEO
William V. Williams, MD
Website
www.briacell.comHeadquarters
West Vancouver, BC V7T 2X1, CA
BCT Financials
Key Financial Metrics (TTM)
Gross Margin
0.00%
Operating Margin
0.00%
Net Income Margin
0.00%
Return on Equity
-147.92%
Return on Capital
-153.48%
Return on Assets
-113.23%
Earnings Yield
-3.03%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
CA$48.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
8.70M
Volume
14.49K
Avg. Volume
13.03K
Financials (TTM)
Gross Profit
-$26.59K
Operating Income
-$32.01M
EBITDA
-$31.48M
Operating Cash Flow
-$30.88M
Capital Expenditure
-$129.18K
Free Cash Flow
-$31.01M
Cash & ST Invst.
$22.80M
Total Debt
$0.00
BriaCell Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$0.00
N/A
Gross Margin
0.00%
N/A
Market Cap
CA$48.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
CA$3.03M
N/A
Employees
16
N/A
Net Income
-$7.16M
-16.9%
EBITDA
-$7.17M
-16.4%
Quarterly Fundamentals
Total Cash
$22.80M
+83.0%
Total Debt
$0.00
N/A
Accounts Receivable
$2.59M
+11.3%
Inventory
$0.00
N/A
Long Term Debt
$0.00
N/A
Short Term Debt
$0.00
N/A
Return on Assets
-1.13%
N/A
Return on Invested Capital
-1.36%
N/A
Free Cash Flow
-$7.21M
-0.6%
Operating Cash Flow
-$7.08M
+1.2%